Biosimilar
FDA approves Amgen’s rituximab biosimilar for treatment of moderate-to-severe RA
The FDA has approved rituximab-arrx, in combination with methotrexate, in adult patients with moderate or severely active rheumatoid arthritis who have had inadequate responses to one or more TNF agonist therapies.
FDA approves Amgen’s rituximab biosimilar for treatment of moderate-to-severe RA
The FDA has approved rituximab-arrx, in combination with methotrexate, in adult patients with moderate or severely active rheumatoid arthritis who have had inadequate responses to one or more TNF agonist therapies.
Ustekinumab biosimilar candidate achieves ‘therapeutic equivalence’
AVT04, a biosimilar candidate to ustekinumab developed by Alvotech, met the primary endpoint in a confirmatory clinical study of patients with chronic plaque-type psoriasis, according to a company press.
Biosimilar comparable to trastuzumab in efficacy for breast cancer subset
HD201, a trastuzumab biosimilar candidate, demonstrated equivalent efficacy to referent trastuzumab among patients with ERBB2-positive early breast cancer, according to phase 3 study results published in JAMA Oncology.
Upcoming biosimilar logjam could provide cost savings for arthritis drugs
The upcoming influx of new biosimilar drugs to the market could mitigate the cost of biologics to treat inflammatory diseases, said Steven Newmark, director of policy and chief legal officer for the Global Healthy Living Foundation.
Surge in specialty drug use ‘largely driven’ by autoimmune disease
Autoimmune treatments accounted for more than half of all specialty drug growth in 2021, according to a drug trend report released by CVS Health.
Nonprofit to offer biosimilar insulins at low cost regardless of insurance status
The nonprofit generic pharmaceutical company Civica will manufacture and distribute biosimilar versions of three widely prescribed insulins priced at $30 per vial or $55 for five pens, according to a press release from JDRF.
Most rheumatologists 'unlikely' to switch to biosimilars until greater payer adoption
Despite an overwhelming majority of rheumatologists reporting comfort and familiarity with biosimilars, 65% said they are “unlikely” to switch their patients from reference products until there is greater payer adoption, according to data.
Norway 'excellent example' of how to increase access to biosimilars
The European Union, and specifically Norway, has demonstrated successful strategies for making biosimilars available for patients — and realizing “tremendous savings” — that should be adopted in the United States, according to an analysis.
Biosimilar, originator DMARDs exhibit no differences in treatment retention
There are no clinically relevant differences in treatment retention among patients receiving biosimilar or originator biologic disease-modifying antirheumatic drugs as first exposure to that drug, data published in Rheumatology show.